Telaglenastat
Telaglenastat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against glutaminase kidney isoform, mitochondrial.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 5 | 4 | — | — | — | 6 | ||
| Renal cell carcinoma | D002292 | 3 | 4 | — | — | — | 5 | ||
| Neoplasms | D009369 | C80 | 5 | 3 | — | — | — | 5 | |
| Triple negative breast neoplasms | D064726 | 2 | 2 | — | — | — | 3 | ||
| Colorectal neoplasms | D015179 | 3 | 3 | — | — | — | 3 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 2 | 1 | — | — | — | 2 | |
| Lung neoplasms | D008175 | C34.90 | 2 | 1 | — | — | — | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | 1 | — | — | — | 1 | |
| Colonic neoplasms | D003110 | C18 | 1 | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 2 | — | — | — | — | 2 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Mesothelioma | D008654 | C45 | 1 | — | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | 1 | — | — | — | — | 1 | |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Astrocytoma | D001254 | EFO_0000271 | 1 | — | — | — | — | 1 | |
| Meningeal neoplasms | D008577 | EFO_0003851 | C70 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TELAGLENASTAT |
| INN | telaglenastat |
| Description | Telaglenastat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against glutaminase kidney isoform, mitochondrial. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: glutaminase inhibitor |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1 |
Identifiers
| PDB | — |
| CAS-ID | 1439399-58-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3639788 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | U6CL98GLP4 (ChemIDplus, GSRS) |
Target
Agency Approved
GLS
GLS
Organism
Homo sapiens
Gene name
GLS
Gene synonyms
GLS1, KIAA0838
NCBI Gene ID
Protein name
glutaminase kidney isoform, mitochondrial
Protein synonyms
glutaminase C, glutaminase, phosphate-activated, K-glutaminase, L-glutamine amidohydrolase
Uniprot ID
Mouse ortholog
Gls (14660)
glutaminase kidney isoform, mitochondrial (Q69ZX9)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 242 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more